Another reason for the low objective response rate in PD-1/PD-L1 blockade therapy is that induced tumor-targeted CTLs are quickly exhausted in the tumor microenvironment so they cannot provide a sustainable and powerful anti-tumor effect (108). Here, PDCD1 is linked to neoplasm.